{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T02:15:36Z","timestamp":1790129736988,"version":"4.0.1"},"reference-count":37,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","award":["CRP-17-111-01-CDD"],"award-info":[{"award-number":["CRP-17-111-01-CDD"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008478","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008478","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001685","name":"European School of Oncology","doi-asserted-by":"publisher","award":["P30CA008748"],"award-info":[{"award-number":["P30CA008748"]}],"id":[{"id":"10.13039\/501100001685","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA220497"],"award-info":[{"award-number":["CA220497"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005410","name":"American-Italian Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005410","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005927","name":"Daiichi Sankyo Foundation of Life Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005927","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007886","name":"Dana-Farber Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007886","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jto.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.jtho.2025.03.045","type":"journal-article","created":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T23:37:41Z","timestamp":1743637061000},"page":"1035-1049","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Activating Mutations in the MET Kinase Domain Co-Occur With Other Driver Oncogenes and Mediate Resistance to Targeted Therapy in NSCLC"],"prefix":"10.1016","volume":"20","author":[{"given":"Seshiru","family":"Nakazawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Pecci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biagio","family":"Ricciuti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix H.","family":"Gottlieb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Facchinetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guilherme","family":"Harada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica F.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Repetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavia","family":"Giacomini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Ana\u00efs","family":"Locquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maisam","family":"Makarem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joao V.","family":"Alessi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Di Federico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihaela","family":"Aldea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo","family":"Garbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malini M.","family":"Gandhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arushi","family":"Saini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Haradon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magda","family":"Bahcall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William W.","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica K.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexa B.","family":"Schrock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Drilon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark M.","family":"Awad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasi A.","family":"J\u00e4nne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtho.2025.03.045_bib1","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1158\/2159-8290.CD-21-0124","article-title":"The promising evolution of targeted therapeutic strategies in cancer","volume":"11","author":"Peters","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtho.2025.03.045_bib2","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1038\/bjc.2015.356","article-title":"Overall survival benefits of first-line EGFR tyrosine kinase inhibitors in EGFR-mutated non-small-cell lung cancers: a systematic review and meta-analysis","volume":"113","author":"Kuan","year":"2015","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jtho.2025.03.045_bib3","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41416-019-0573-8","article-title":"Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer","volume":"121","author":"Leonetti","year":"2019","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jtho.2025.03.045_bib4","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41586-021-04065-2","article-title":"Diverse alterations associated with resistance to KRAS(G12C) inhibition","volume":"599","author":"Zhao","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.jtho.2025.03.045_bib5","doi-asserted-by":"crossref","first-page":"3334","DOI":"10.1158\/1078-0432.CCR-17-2452","article-title":"Resistance mechanisms to targeted therapies in ROS1+ and ALK+ non-small cell lung cancer","volume":"24","author":"McCoach","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2025.03.045_bib6","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1158\/1078-0432.CCR-19-3608","article-title":"Molecular mechanisms of acquired resistance to MET tyrosine kinase inhibitors in patients with MET exon 14-mutant NSCLC","volume":"26","author":"Recondo","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2025.03.045_bib7","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1056\/NEJMoa2105281","article-title":"Acquired resistance to KRASG12C inhibition in cancer","volume":"384","author":"Awad","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2025.03.045_bib8","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1158\/1078-0432.CCR-21-0032","article-title":"Spectrum of mechanisms of resistance to crizotinib and lorlatinib in ROS1 fusion-positive lung cancer","volume":"27","author":"Lin","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2025.03.045_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2023.107006","article-title":"Overcoming MET-mediated resistance in oncogene-driven NSCLC","volume":"26","author":"Reischmann","year":"2023","journal-title":"iScience"},{"key":"10.1016\/j.jtho.2025.03.045_bib10","article-title":"The efficacy and safety of treating acquired MET resistance through combinations of parent and MET tyrosine kinase inhibitors in patients with metastatic oncogene-driven NSCLC","volume":"5","author":"Patil","year":"2024","journal-title":"JTO Clin Res Rep"},{"key":"10.1016\/j.jtho.2025.03.045_bib11","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1200\/JCO.18.00177","article-title":"Clonal MET amplification as a determinant of tyrosine kinase inhibitor resistance in epidermal growth factor receptor-mutant non-small-cell lung cancer","volume":"37","author":"Lai","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2025.03.045_bib12","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1111\/1759-7714.14656","article-title":"MET gene amplification is a mechanism of resistance to entrectinib in ROS1+ NSCLC","volume":"13","author":"Tyler","year":"2022","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.jtho.2025.03.045_bib13","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1158\/1078-0432.CCR-19-3906","article-title":"MET alterations are a recurring and actionable resistance mechanism in ALK-positive lung cancer","volume":"26","author":"Dagogo-Jack","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2025.03.045_bib14","doi-asserted-by":"crossref","first-page":"e851","DOI":"10.1016\/j.cllc.2021.04.008","article-title":"Early alectinib resistance from MET amplification in ALK-rearranged NSCLC: response to crizotinib with re-response to alectinib and crizotinib","volume":"22","author":"Ji","year":"2021","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.jtho.2025.03.045_bib15","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1056\/NEJMoa1505917","article-title":"Comprehensive molecular characterization of papillary renal-cell carcinoma","volume":"374","author":"Cancer Genome Atlas Research Network","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2025.03.045_bib16","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1158\/2159-8290.CD-23-1217","article-title":"Activating point mutations in the MET kinase domain represent a unique molecular subset of lung cancer and other malignancies targetable with MET inhibitors","volume":"14","author":"Pecci","year":"2024","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtho.2025.03.045_bib17","doi-asserted-by":"crossref","first-page":"4264","DOI":"10.1038\/s41467-022-31780-9","article-title":"Landscape of somatic alterations in large-scale solid tumors from an Asian population","volume":"13","author":"Wu","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtho.2025.03.045_bib18","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/j.annonc.2022.09.151","article-title":"APOBEC mutagenesis, kataegis, chromothripsis in EGFR-mutant osimertinib-resistant lung adenocarcinomas","volume":"33","author":"Selenica","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2025.03.045_bib19","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1038\/s41588-019-0390-2","article-title":"Detecting the mutational signature of homologous recombination deficiency in clinical samples","volume":"51","author":"Gulhan","year":"2019","journal-title":"Nat Genet"},{"key":"10.1016\/j.jtho.2025.03.045_bib20","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nature12477","article-title":"Signatures of mutational processes in human cancer","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.jtho.2025.03.045_bib21","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1093\/bioinformatics\/btw230","article-title":"Combenefit: an interactive platform for the analysis and visualization of drug combinations","volume":"32","author":"Di Veroli","year":"2016","journal-title":"Bioinformatics"},{"key":"10.1016\/j.jtho.2025.03.045_bib22","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1158\/2159-8290.CD-23-0467","article-title":"Quantifying the expanding landscape of clinical actionability for patients with cancer","volume":"14","author":"Suehnholz","year":"2024","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtho.2025.03.045_bib23","article-title":"OncoKB: A precision oncology knowledge base","volume":"2017","author":"Chakravarty","year":"2017","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.jtho.2025.03.045_bib24","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1016\/j.jtho.2019.06.023","article-title":"Sensitivity and resistance of MET Exon 14 mutations in lung cancer to eight MET tyrosine kinase inhibitors in vitro","volume":"14","author":"Fujino","year":"2019","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.03.045_bib25","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1158\/1535-7163.MCT-21-0344","article-title":"Combination of type I and Type II MET tyrosine kinase inhibitors as therapeutic approach to prevent resistance","volume":"21","author":"Bahcall","year":"2022","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.jtho.2025.03.045_bib26","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41698-023-00464-y","article-title":"Lorlatinib and capmatinib in a ROS1-rearranged NSCLC with MET-driven resistance: tumor response and evolution","volume":"7","author":"Schneider","year":"2023","journal-title":"npj Precis Oncol"},{"key":"10.1016\/j.jtho.2025.03.045_bib27","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1158\/2159-8290.CD-16-0686","article-title":"Acquired METD1228V mutation and resistance to MET inhibition in lung cancer","volume":"6","author":"Bahcall","year":"2016","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtho.2025.03.045_bib28","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s13045-022-01299-z","article-title":"Foretinib can overcome common on-target resistance mutations after capmatinib\/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation","volume":"15","author":"Fujino","year":"2022","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.jtho.2025.03.045_bib29","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1158\/2159-8290.CD-24-0027","article-title":"Translational and therapeutic evaluation of RAS-GTP inhibition by RMC-6236 in RAS-driven cancers","volume":"14","author":"Jiang","year":"2024","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtho.2025.03.045_bib30","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1158\/1078-0432.CCR-19-3563","article-title":"Tumor analyses reveal squamous transformation and off-target alterations as early resistance mechanisms to first-line osimertinib in EGFR-mutant lung cancer","volume":"26","author":"Schoenfeld","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2025.03.045_bib31","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12931-023-02329-1","article-title":"Mutations in the MET tyrosine kinase domain and resistance to tyrosine kinase inhibitors in non-small-cell lung cancer","volume":"24","author":"Yao","year":"2023","journal-title":"Respir Res"},{"key":"10.1016\/j.jtho.2025.03.045_bib32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2021.06.043","article-title":"Resistance profiles of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced non-small-cell lung cancer: a multicenter study using targeted next-generation sequencing","volume":"156","author":"Lin","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jtho.2025.03.045_bib33","doi-asserted-by":"crossref","first-page":"3400","DOI":"10.1200\/JCO.24.00581","article-title":"Lorlatinib versus crizotinib in patients with advanced ALK-positive non-small cell lung cancer: 5-year outcomes from the phase III CROWN study","volume":"42","author":"Solomon","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2025.03.045_bib34","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1038\/s41467-023-35961-y","article-title":"Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer","volume":"14","author":"Chmielecki","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtho.2025.03.045_bib35","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.1200\/JCO.2018.77.7326","article-title":"Phase Ib\/II study of capmatinib (INC280) plus gefitinib after failure of epidermal growth factor receptor (EGFR) inhibitor therapy in patients with EGFR-mutated, MET factor-dysregulated non-small-cell lung cancer","volume":"36","author":"Wu","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2025.03.045_bib36","article-title":"Efficacy and tolerability of ALK\/MET combinations in patients with ALK-rearranged lung cancer with acquired MET amplification: a retrospective analysis","volume":"4","author":"Dagogo-Jack","year":"2023","journal-title":"JTO Clin Res Rep"},{"key":"10.1016\/j.jtho.2025.03.045_bib37","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/nm.4040","article-title":"Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition","volume":"22","author":"Hata","year":"2016","journal-title":"Nat Med"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086425006501?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086425006501?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T02:16:53Z","timestamp":1785550613000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086425006501"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":37,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S1556086425006501"],"URL":"https:\/\/doi.org\/10.1016\/j.jtho.2025.03.045","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Activating Mutations in the MET Kinase Domain Co-Occur With Other Driver Oncogenes and Mediate Resistance to Targeted Therapy in NSCLC","name":"articletitle","label":"Article Title"},{"value":"Journal of Thoracic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2025.03.045","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 International Association for the Study of Lung Cancer. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}